SCLX
Scilex Holding CompanyNASDAQ
Healthcare • Drug Manufacturers - General
$1.700.00%
Close Nov 6, 2026
- Market cap
- $11.72M
- 1 month
- -42.6%
- 3 months
- -74.6%
- 1 year
- -85.2%
- Dividend
- No dividends on record
- Short interest
- 2.6% of float148.4K shares · settled Oct 15, 2026 · -13.3% since Sep 30, 2026 · FINRA
Fundamentals · trailing 12 months to Jun 30, 2026
- Revenue
- $31.61M
- Net income
- -$447.12M
- Free cash flow
- -$17.46M
- Book value
- —
- Total debt
- $95.56M
- P/E
- —
- Price / sales
- 0.4×
- Price / book
- —
- FCF yield
- -149.0%
- Net margin
- -1,414.6%
EODHD (TTM) · as of Nov 6, 2026
End-of-day close from stored market data, not a live quote.
About Scilex Holding Company
Scilex Holding Company focuses on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain.
Read more
Its commercial products include ZTlido (lidocaine topical system) 1.8% (ZTlido), a prescription lidocaine topical product for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a ready-to-use oral solution for the acute treatment of migraine with or without aura in adults; and GLOPERBA, a liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults. The company also develops three product candidates, including SP-102 (10 mg, dexamethasone sodium phosphate viscous gel - SEMDEXA), a novel viscous gel formulation of a used corticosteroid for epidural injections, which has completed a phase 3 study to treat lumbosacral radicular pain or sciatica; SP-103 (lidocaine topical system) 5.4%, a formulation of ZTlido for the treatment of chronic neck pain and low back pain (LBP) that has completed a phase 2 trial; and SP-104 (4.5 mg low-dose naltrexone hydrochloride delayed-release capsules), a novel low-dose delayed-release naltrexone hydrochloride, which has completed phase 1 trials for the treatment of fibromyalgia. It has an agreement with Oishi and Itochu to develop lidocaine tape products, including ZTlido and SP-103; Lifecore Biomedical, LLC for clinical trial material manufacturing and development services for SEMDEXA; and Tulex Master, which develops, tests, and manufactures clinical supplies of SP-104. Scilex Holding Company is based in Palo Alto, California.
- Website
- scilexholding.com
- Headquarters
- Palo Alto, CA, United States
- Employees
- 34
- Listed
- Mar 5, 2021
- Fiscal year ends
- December
Company profile from EODHD, stored Nov 1, 2026.
Quarterly results
The last 8 fiscal quarters as reported (EODHD). Year over year compares the same quarter a year earlier.
| Quarter | Revenue | YoY | Gross margin | Op. income | Net income |
|---|---|---|---|---|---|
| Jun 2026filed Aug 14, 2026 | $7.6M | -22.8% | 14.7% | -$29.4M | -$113.5M |
| Mar 2026filed May 20, 2026 | $8.6M | +72.1% | 48.4% | -$32.2M | -$43.3M |
| Dec 2025 | $4.8M | -67.8% | 45.5% | -$37.5M | -$33.1M |
| Sep 2025filed Nov 14, 2025 | $10.6M | -26.8% | 68.5% | -$186.5M | -$257.2M |
| Jun 2025filed Aug 13, 2025 | $9.9M | -39.5% | 66.9% | -$20.5M | -$86.1M |
| Mar 2025filed May 14, 2025 | $5.0M | -54.0% | 72.3% | -$27.9M | -$26.1M |
| Dec 2024filed Mar 31, 2025 | $14.9M | +10.7% | 68.5% | -$28.4M | -$6.5M |
| Sep 2024 | $14.4M | +42.7% | 73.9% | -$22.4M | -$4.4M |
Fiscal years · last 6
| Fiscal year | Revenue | YoY | Gross margin | Op. income | Net income |
|---|---|---|---|---|---|
| Dec 2025filed Apr 10, 2026 | $30.3M | -46.5% | 49.7% | -$272.3M | -$358.7M |
| Dec 2024filed Mar 31, 2025 | $56.6M | +21.1% | 70.5% | -$83.4M | -$72.8M |
| Dec 2023filed Mar 12, 2024 | $46.7M | +22.9% | 66.5% | -$105.4M | -$114.3M |
| Dec 2022filed Mar 7, 2023 | $38.0M | +21.4% | 71.6% | -$50.6M | -$23.4M |
| Dec 2021filed Dec 31, 2021 | $31.3M | +32.9% | 88.4% | -$35.8M | -$88.4M |
| Dec 2020filed Dec 31, 2020 | $23.6M | +12.0% | 90.9% | -$35.3M | -$47.5M |
Short-interest history
FINRA reports open short positions for a settlement date. The publication date is later. These are reported positions, with a separate date for each observation.
Compare the reported short exposure around the dates you bought, sold or watched SCLX. A long position benefits from price rises; a short position benefits from falls. A change in these counts does not predict either move.
Settlement Oct 15, 2026
148,382 shares short
-22,769 shares (-13.3%) vs Sep 30, 2026
2.6% of the stored float. Published Oct 26, 2026.
Settlement Sep 30, 2026
171,151 shares short
-5,560 shares (-3.1%) vs Sep 15, 2026
3% of the stored float. Published Oct 9, 2026.
Settlement Sep 15, 2026
176,711 shares short
+17,789 shares (+11.2%) vs Aug 31, 2026
3.1% of the stored float. Published Sep 24, 2026.
Settlement Aug 31, 2026
158,922 shares short
+6,337 shares (+4.2%) vs Aug 14, 2026
2.8% of the stored float. Published Sep 10, 2026.
Settlement Aug 14, 2026
152,585 shares short
-22,952 shares (-13.1%) vs Jul 31, 2026
Share of float unavailable. Published Aug 25, 2026.
Settlement Jul 31, 2026
175,537 shares short
-33,687 shares (-16.1%) vs Jul 15, 2026
Share of float unavailable. Published Aug 11, 2026.
Change = this settlement’s shares short − the previous recorded settlement’s shares short; percentage change divides by that earlier count. A zero earlier count has no percentage change. Split-spanning counts are left uncompared. Float percentages use the stored settlement observation, not today’s float.
Source: stored FINRA equity short-interest records, up to six settlements from the last 240 days. FINRA data and reporting dates · How to read short interest
Dividends and stock splits
See the recorded cash amounts and dates behind SCLX’s income, and the splits that change its share count. Dates below are stored event records, not confirmation of a payment to your account.
Cash-dividend records
No qualified cash-dividend records are stored. This does not establish that the company pays no dividend.
Up to six Polygon cash-dividend events, including recorded ex-dates within the next 120 days. Amounts retain their recorded currency and decimal precision. Historical amounts are not restated to a common split basis, annualized, or converted to dollars.
For a long holding, compare the ex-date with when you held the shares and check the pay date against your broker’s cash history. Owning the stock today does not establish past entitlement. For a short holding, a dividend can create a payment obligation to the share lender.
Ex-dates and special dividend rules · Short-sale dividend obligations · Dividend data definitions
Split history
803 for 500 · forward split
Effective Jun 16, 2026
Each 500 pre-split shares become 803 post-split shares.
Source: EODHD
1 for 35 · reverse split
Effective Apr 15, 2025
Each 35 pre-split shares become 1 post-split share.
Source: EODHD
Up to six stored split dates through Nov 7, 2026. Equivalent vendor ratios are combined; conflicting ratios are left out. This history may be incomplete.
A split changes the share count and per-share price basis; it does not by itself add investment value. Put your holding’s earlier and later share counts on the same basis before comparing them. This applies to both long shares and shares owed on a short position.
How stock splits workPortfolio context
Sign in to see your position size
We’ll show you if SCLX is in your portfolio and how much it contributes.
Sign inMarket context
Loading market dates
Smart money context
Holder IQ: MEDIUM
9 smart-money holders: institutions with a high Holder IQ
Q2 2026, filed Oct 29, 2026
Insider context
Sentiment: unknown
No recent insider trades detected.
Read the insider context evidence
What it means for you
Sign in to read your holdings or watchlist context. No personal position or direction is inferred.
What happened
No directional recent-activity label is available. This context label is separate from the scored insider signal read.
Why it can matter
A count of reported activity describes a sample, not purchase conviction, an insider’s intent or a future price move. Neutral is not an all-clear, and absent direction is not neutral evidence.
How we got this
The current context rule reads at most 50 nonduplicate issuer/share-class records filed in the last 90 days. It counts a bullish direction or purchase code P toward bullish, and a bearish direction or sale code S toward bearish. A side must exceed the opposite count by more than two to set its label; otherwise nonzero directional counts produce neutral. Calculation unavailable for this saved label: its counts, exact records, as-of time and rule version are not supplied here. Do not substitute the separate scored read’s different window or denominator.
Where the data comes from
Stored SEC Forms 3/4/5 insider-signal records, ordered by filing date with amendment duplicates excluded. Filing date is not transaction date. The last-trade line locates recent reported activity; it does not date or reconstruct the complete count.
Red flags: 0
Read the insider context evidence
What it means for you
Sign in to read your holdings or watchlist context. No personal position or direction is inferred.
What happened
No directional recent-activity label is available. This context label is separate from the scored insider signal read.
Why it can matter
A count of reported activity describes a sample, not purchase conviction, an insider’s intent or a future price move. Neutral is not an all-clear, and absent direction is not neutral evidence.
How we got this
The current context rule reads at most 50 nonduplicate issuer/share-class records filed in the last 90 days. It counts a bullish direction or purchase code P toward bullish, and a bearish direction or sale code S toward bearish. A side must exceed the opposite count by more than two to set its label; otherwise nonzero directional counts produce neutral. Calculation unavailable for this saved label: its counts, exact records, as-of time and rule version are not supplied here. Do not substitute the separate scored read’s different window or denominator.
Where the data comes from
Stored SEC Forms 3/4/5 insider-signal records, ordered by filing date with amendment duplicates excluded. Filing date is not transaction date. The last-trade line locates recent reported activity; it does not date or reconstruct the complete count.
Largest 13-F holders · Q2 2026
72 filers reported a long position in SCLX for Q2 2026. 13-F holdings are filed up to 45 days after the quarter ends.
The top 10 hold
94.8%
of the 702.8K shares 13-F filers reported
Moves vs Q1 2026
5 added1 trimmed
3 new · 1 unchanged
Net shares held
+14.6%
across the 7 holders with a comparable Q1 2026 book
| Rank | Holder | Value | Shares | Shares vs Q1 2026 |
|---|---|---|---|---|
| 1 | VANGUARD CAPITAL MANAGEMENT LLC | $2.4M · 301.3K shares | 301.3K | +14.1% |
| 2 | BlackRock, Inc. | $853.5K · 109.4K shares | 109.4K | +6.4% |
| 3 | VANGUARD FIDUCIARY TRUST CO | $357.4K · 45.8K shares | 45.8K | +15.5% |
| 4 | JACOBS LEVY EQUITY MANAGEMENT, INC | $321.1K · 41.2K shares | 41.2K | New |
| 5 | STATE STREET CORP | $275.9K · 35.4K shares | 35.4K | Unchanged |
| 6 | UBS Group AG | $260.3K · 33.4K shares | 33.4K | +416% |
| 7 | RENAISSANCE TECHNOLOGIES LLC | $257.9K · 33.1K shares | 33.1K | -10.3% |
| 8 | CITADEL ADVISORS LLC | $214.5K · 27.5K shares | 27.5K | New |
| 9 | PRICE T ROWE ASSOCIATES INC /MD/ | $164K · 20.9K shares | 20.9K | New |
| 10 | Ashton Thomas Private Wealth, LLC | $144.2K · 18.5K shares | 18.5K | +2.7% |
Sign in to see each holder’s Holder IQ, factor-adjusted Holder IQ and rank, and compare these holders with all scored filers. Available on every plan.
Sign in5% holder filings (13D / 13G)
Holders of more than 5% of SCLX file with the SEC within days. A 13D holder may seek to influence the company; a 13G holder is passive. Each holder’s latest filing from the last three years.
| Filed | Holder | % of class |
|---|---|---|
| Jul 7, 2026 | SCLX Stock Acquisition JV LLC13D · activist · amended | 11.4% |
Get the Full Analysis for SCLX
Unlock detailed insider transactions, institutional holder changes, factor exposures, and personalized alerts. Start free with your own portfolio.